Anti-GFAP autoantibodies have been preliminarily reported in other human disorders, such as in patients with Alzheimer’s disease or other dementias [18],[19],[52]–[54], stroke [16],[55], diabetes [56], neurological disorders, multiple sclerosis [57],[58], autism [59] and lead-exposed workers [60]. Here, GFAP is linked to Alzheimer disease.